Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Search
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Brinjal Chutney Video
Find out how to make authentic brinjal chutney from Taking Cancer On Through Flavour
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
Crockpot Garlic Chicken video
Find out how to make this hearty, slow-cooked chicken recipe from Taking Cancer on Through Flavour and Taste Life.
Banana Nice Cream Video
This rich and creamy banana ice cream is easy to make and freshing to eat. Made using dairy-free milks and with no added sugars, it is the perfect way to satisfy a sweet craving.
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Hypertension
Click here for more information on Hypertension
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Angels Initiative in South Africa
Dr Stacey Rossouw explains how the Angels initiative is making a difference in South Africa and optimizing stroke care
LUX-Lung 7 & 8 Trials
.
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
Global language learning platform for our people
One global learning platform for languages, countless opportunities to grow your career
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Understanding the language of dogs
Dogs are our best friends - however, communicating with them is not always easy. Let’s bust a few myths about our four-legged friends and how we can interact with them.
Immuno-Oncology
We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Living with GPP
Video content showing a patient’s perspective of living with generalized pustular psoriasis (GPP), a rare skin condition
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Hidradenitis suppurativa
Find out more about hidradenitis suppurativa (HS), a long-term, inflammatory, recurrent, skin disease